In this issue:
- First-line serplulimab + chemotherapy in extensivestage SCLC
- Nivolumab + ipilimumab ±SBRT for advanced MCC
- Adjuvant atezolizumab for RCC at increased recurrence risk postresection
- Adjuvant pembrolizumab in resected stage IIB or IIC melanoma
- Neoadjuvant cemiplimab for stage II–IV cutaneous SCC
- First-line avelumab for PD-L1- positive metastatic or locally advanced urothelial cancer
- Pembrolizumab in MSI-high or mismatch repair deficient cancers
- Nivolumab + low-dose ipilimumab in pretreated MSI-high/mismatch repair-deficient metastatic CRC
- QOL for persistent immunerelated adverse events after ICI cessation
- Nivolumab-ipilimumabcabozantinib triplet for previously untreated advanced RCC
- CV events in ICI recipients
Download PDF